Long-term Biological Treatment in Juvenile Idiopathic Arthritis: Benefits and Risks

Duca Emanuela^{1, 2}, Harabagiu Marin³, Maguran Ioana², Samasca Gabriel² and Sur Genel^{1, 2,}

¹Iuliu Hatieganu University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania

²Children Emergency Clinical Hospital, 400370 Cluj-Napoca, Romania

³Clinical Hospital of Infectious Diseases, 400000, Cluj-Napoca, Romania

Cite this paper:
Duca Emanuela, Harabagiu Marin, Maguran Ioana, Samasca Gabriel and Sur Genel. Long-term Biological Treatment in Juvenile Idiopathic Arthritis: Benefits and Risks. International Journal of Celiac Disease. 2022; 10(1):17-19. doi: 10.12691/ijcd-10-1-5

Abstract

The advent of biologic medication has substantially improved the evolution of juvenile idiopathic arthritis (JIA), producing better social insertion and a clearly superior quality of life. However, there is a possibility of immunological disorders following treatment with biological substances, which may have long-term consequences in treated patients. The extension of clinical trials to pediatric patients has allowed a closer follow-up of both the evolution of the disease under treatment and the consequences of biological treatments. This article aims to analyze this aspect according to studies conducted in many countries by several authors. For each biological agent, the immunological events consisted primarily of the appearance of serious infections, such as tuberculosis, malignancies, response to vaccines, the appearance of autoimmune manifestations, and, last but not least, the appearance of anti-drug antibodies. These studies have shown that there are large differences in side effects between different biological agents, and, therefore, it has been proposed that a dossier be conducted to monitor these side effects. An international pharmacovigilance database called PharmaChild has already been created.

Keywords:
juvenile idiopathic arthritis biologic medication benefits risks

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Swart JF, de Roock S, Wulffraat NM. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Research & Therapy 2013; 15: 213.
[2]	Sur L, Sur G, Samasca G, Lupan I. Investigations of cellular immunity in juvenile idiopathic arthritis. Cent Eur J Immunol 2019; 44: 92-96.
[3]	Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis 2018; 77: 1710-1719.
[4]	Ruperto N, Brunner HI, Zuber Z, Tzaribachev N, Kingsbury DJ, Foeldvari I, et al. Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study. Pediatr Rheumatol Online J 2017; 15: 86.
[5]	Sur LM, Floca E, Sur DG, Colceriu MC, Samasca G, Sur G. Antinuclear Antibodies: Marker of Diagnosis and Evolution in Autoimmune Diseases. Lab Med 2018; 49: e62–e73.
[6]	Imagawa T, Yokota S, Mori M, Miyamae T, Takei S, Imanaka H, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012; 22: 109-115.
[7]	Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2015; 74: 1110-1117.
[8]	Nigrovic PA, Colbert RA, Holers VM, Ozen S, Ruperto N, Thompson SD, et al. Biological classification of childhood arthritis: roadmap to a molecular nomenclature. Nat Rev Rheumatol, 2021; 17: 257-269.
[9]	Gerss J, Tedy M, Klein A, Horneff G, Miranda-Garcia M, Kessel C, et al. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis 2022 Mar 8; annrheumdis-2021-222029.
[10]	Nagy A, Mosdosi B, Simon D, Dergez T, Berki T. Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study. Front. Pediatr 2020; 8: 614354.
[11]	Brunner HI, Quartier P, Alexeeva E, Constantin T, Koné-Paut I, Marzan K, et al. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis Rheumatol 2020; 72: 2147-2158.
[12]	Sur LM, Gaga R, Duca E, Sur G, Lupan I, Sur D, et al. Different Chronic Disorders That Fall within the Term Juvenile Idiopathic Arthritis. Life 2021; 11: 398.
[13]	Wu J, Sun L, Tang X, Zheng Q, Guo L, Xu L, et al. Effective therapy of tocilizumab on systemic juvenile idiopathic arthritis–associated refractory macrophage activation syndrome. Mod Rheumatol 2021.
[14]	Sur LM, Silaghi C, Colceriu MC, Sur DG, Aldea C, Sur G, et al. Immunology markers that can be predictive for the diagnosis of juvenile idiopathic arthritis. Journal of Laboratory Medicine 2020; 44: 23-26.
[15]	Sur LM, Armat I, Duca E, Sur G, Lupan I, Sur D, et al. Food Allergy a Constant Concern to the Medical World and Healthcare Providers: Practical Aspects. Life 2021; 11: 1204.
[16]	Katsicas, M.M., Russo, R.A.G. (2020). Systemic-Onset Juvenile Idiopathic Arthritis. In: Cimaz, R. (eds) Periodic and Non-Periodic Fevers. Rare Diseases of the Immune System. Springer, Cham.
[17]	Florian A, Lupan I, Sur L, Samasca G, Florian T. To be, or not to be… Guillain-Barré Syndrome. Autoimmun Rev 2021; 20: 102983.
[18]	Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Koskinen LO, Kullenberg T, et al. Anakinra in children and adults with Still’s disease. Rheumatology 2019; 58: vi9-vi22.
[19]	Sur L, Gaga R, Lazar C, Lazea C, Aldea C, Sur D. Papillary thyroid carcinoma in children with Hashimoto's thyroiditis-A review of the literature between 2000 and 2020. J Pediatr Endocrinol Metabol 2020; 33: 1511-1517.
[20]	Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008; 359: 810-820.